Buscar en
Farmacia Hospitalaria (English Edition)
Toda la web
Inicio Farmacia Hospitalaria (English Edition) Indications for the use of next-generation antiretroviral drugs in current clini...
Información de la revista
Vol. 35. Núm. 1.
Páginas 14-22 (Enero 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 35. Núm. 1.
Páginas 14-22 (Enero 2011)
Original Article
Acceso a texto completo
Indications for the use of next-generation antiretroviral drugs in current clinical practice
Indicación de uso de los antirretrovirales de última generación en la práctica clínica actual
Visitas
...
I. Castillo Romeraa,
Autor para correspondencia
, A. Ais Larisgoitiaa, A.N. Trovato Lópeza, V. Escudero Villaplanaa, J.M. Bellón Canob, M. Sanjurjo Saéza
a Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, Spain
b Servicio de Medicina y Preventiva, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Información del artículo
Abstract
Objective

To describe the indications for use, in medical practice, of next-generation antiretroviral drugs (NGA): darunavir, raltegravir, maraviroc and etravirine.

Method

An observational, transversal and descriptive study conducted in adult patients who have started to receive a NGA between May 2008 and April 2009. The variables associated with the use of NGA were defined as follows: a) Variables related to efficacy: resistance confirmed by geno/phenotype tests or potencial resistance as a result of extensive exposure to antiretroviral agents, and/or severe immunological deterioration (CD4 less than 200 cells/mcl). b) Variables related to safety: prior toxicity to classic antiretroviral drugs and/or comorbidity which compromises their use. c) Combined efficacy and safety variable (main variable): prioritizing the variables which were detected, the patients were classified into three groups: multiresistant geno/phenotype (multi-G/P), multiresistant as a result of treatment history and other situations. Data was obtained from electronic medical records, laboratory tests, and records of interviews and drugs dispensed by the Pharmacy Service.

Results

Seventy three patients, 40% of whom had an undetectable viral load and 38.4% who showed severe immunological deterioration, were included in the study. Multi-G/P occurred in 45% and multiresistance as a result of treatment history was found in 33% of patients. Patients classified as belonging to the “other situations”ategory were characterized by having a greater viral load and a poorer immunological status. In 90% of the patients without multi-G/P two or more variables associated with the use of NGA were detected.

Discussion

The medical reality of using NGA shows that they play a role in clinical situations which are very different, specific and difficult to manage.

Keywords:
Darunavir
Maraviroc
Etravirine
Raltegravir
Multiple drug resistance
Antiretroviral treatment
HIV infection
Resumen
Objetivo

Describir el perfil de utilización en la práctica asistencial de los antirretrovirales de última generación (AUG): darunavir, raltegravir, maraviroc y etravirina.

Método

Estudio observacional, transversal y descriptivo realizado en pacientes adultos que hubiesen iniciado tratamiento con algún AUG entre mayo de 2008 y abril de 2009. Se definieron las variables asociadas al uso de AUG: a) relacionadas con la eficacia: resistencias según pruebas geno/fenotípicas, o potenciales por amplia experiencia previa a antirretrovirales; y/o deterioro inmunológico grave (CD4 inferior a 200 células/mcl). b) Relacionadas con la seguridad: toxicidad previa a antirretrovirales clásicos, y/o comorbilidad que condiciona su uso. c) Variable combinada de eficacia y seguridad (variable principal): priorizando las variables detectadas se clasificaron a los pacientes como multirresistencia geno/fenotípica (multi-G/F), mutirresistencia según histórico de tratamiento, y otras situaciones. Los datos se obtuvieron de la historia clínica informatizada, las pruebas de laboratorio, y el registro de la entrevista y las dispensaciones del Servicio de Farmacia.

Resultados

Se incluyeron 73 pacientes de los que el 40% tenía carga viral indetectable y el 38,4% deterioro inmunológico grave. La multi-G/F ocurrió en el 45%, y la multirresistencia según histórico en el 33% de los pacientes. Los pacientes clasificados como «otras situaciones» se caracterizaron por tener mayor carga viral y peor situación inmunológica. De los pacientes que no presentaron multi-G/F en el 90% se detectaron dos o más variables asociadas al uso de AUG.

Discusión

La realidad asistencial del uso de los AUG muestra su papel en situaciones clínicas muy variadas, particulares y difíciles de manejar.

Palabras clave:
Darunavir
Maraviroc
Etravirina
Raltegravir
Resistencia multiple a medicamentos
Tratamiento antirretroviral
Infección por VIH
El Texto completo está disponible en PDF
References
[1.]
Prezista; Isentress, Celsentri y/o Intelence. EPARs for authorised medicinal products for human use [internet database]. London: European Medicines Agency;1995 [accessed 2009 May 31]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/.
[2.]
J.V. Madruga, D. Berger, M. Mcmurchie, F. Suter, D. Banhegyi, D. Norris, et al.
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatmentexperienced. HIV-infected patients in TITAN: a randomised controlled phase III trial.
[3.]
A.M. Mills, M. Nelson, D. Jayawewra, K. Ruxrungtham, I. Cassetti, P.M. Girard, et al.
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive HIV-1-infected patients: 96-week analysis.
[4.]
M. Markowitz, B.Y. Nguyen, E. Gotuzzo, F. Mendo, Ratanasuwan, C. Kovacs, et al.
Rapid and durable antiretroviral effects of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study.
J Acquir Immune Defic Syndr, 46 (2007), pp. 125-133
[5.]
Markowitz M, Nguyen B-Y, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients: 96-week data. VIII International AIDS Conference. Méjico: 2008. [Accessed 2009 Aug 31]. Available from: http://www.aids2008.org/Pag/Abstracts.aspx?AID=12691.
[6.]
J. Lennox, E. DeJesus, A. Lazzarin, R. Pollard, J. Valdez Ramalho Madruga, J. Zhao, STARTMRK, et al.
A Phase III Study of the Safety & Efficacy of Raltegravir (RAL)-Based vs Efavirenz (EFV)- Based Combination Therapy in Treatment-Naïve HIV-Infected Patients.
ICAAC-IDSA,
[7.]
J. Lennox, E. Dejesus, A. Lazzarin, R. Pollard, J. Madruga, J. Zhao, et al.
Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir-based vs Efavirenz-based Combination Therapy in Treatment-naïve HIV-infected Patients CROI.
Montreal,
[8.]
J. Heera, P. Ive, M. Botes, E. DeJesus, H. Mayer, J. Goodrich, et al.
The MERIT Study of Maraviroc in Antiretroviral-Naive Patients With R5 HIV-1: 96-Week Results. 5th IAS Conference on HIV Pathogenesis,Treatment and Prevention.
Cape Town,
[9.]
M. Markowitz, B.Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, et al.
Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
J Acquir Immune Defic Syndr, 46 (2007), pp. 125-133
[10.]
B. Grinsztejn, B.Y. Nguyen, C. Katlama, J.M. Gatell, A. Lazzarin, D. Vittecoq, et al.
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Lancet, 369 (2007), pp. 1261-1269
[11.]
S.G. Papendorp, van den Berk GE.
Preoperative use of raltegravircontaining regimen as induction therapy: very rapid decline of HIV-1 viral load.
[12.]
R.M. Gulick, J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, A. Horban, et al.
MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection.
N Engl J Med, 359 (2008), pp. 1429-1441
[13.]
Arribas JR.
Papel de las nuevas moléculas en el tratamiento antirretroviral. Dónde situar el raltegravir.
Enferm Infecc Microbiol Clin, 26 (2008), pp. 53-59
[14.]
Panel de expertos de GESIDA y Plan Nacional sobre el Sida. Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antiretroviral en adultos infectados por el virus de la inmunodeficiencia humana. (Updated 2009 Feb). [Accessed 2009 May 31]. Available from: http://www.gesida. seimc.org/index.asp.
[15.]
J. Eron, J. Andrade, R. Zajdenverg, C. Workman, D.A. Cooper, B. Young, et al.
SWITCHMRK 1 and 2 P032 & 033 Switching from Stable Lopinavir/Ritonavir (LPV/r)-Based to Raltegravir (RAL)-Based Combination Antiretroviral Therapy (ART) Resulted In a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24.
CROI. Montreal,
[16.]
Darunavir, Maraviroc, Raltegravir y/o Etravirina. Informes de evaluación con metodología del Grupo Génesis de los siguientes hospitales: H.U. de Bellvitge, H.U. Virgen del Rocío, H.G.U. de Alicante, H.U. Son Dureta, GFT de Hospitales de Andalucía, H.U. Reina Sofía, H. Virgen de la Arrixaca, H. de Galdakao, H.C.U. A Coruña, H.C.U. de Valladolid, H. Son Llàtzer. [Accessed 2009 May 31]. Available from: http://genesis.sefh.es/Enlaces/InformesHospitales.htm.
[17.]
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1–139. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGLpdf.
[18.]
P.S. Belperio, L.A. Mole, D.B. Boothroyd, L.I. Backus.
Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the department of veterans affairs.
[19.]
M.T. Martín, E. Del Cacho, E. López, C. Codina, M. Tuset, E. De Lazzari, et al.
Reacciones adversas del tratamiento antiretroviral: relación entre los síntomas percibidos y el cumplimiento terapéutico.
Med Clin (Barc), 129 (2007), pp. 127-133
[20.]
D.M. Zuk, C.A. Hughes, M.M. Foisy, J.L. Robinson, A.E. Singh, S. Houston.
Adverse effects of antiretrovirals in HIV-infected pregnant woman.
Ann Pharmacother, 43 (2009), pp. 1028-1035
[21.]
Kim E, Grimm K, Oza D, Zoe Powers A. Correlates of Adherence and Non-Adherence to HIV Treatment Medications: A National Cross-Sectional Survey. Program and abstracts: 4th International Conference on HIV Treatment Adherence. Miami. 2009. Abstract: 224.
[22.]
A. Ammassari, M.P. Trotta, P. Marconi, M. Zaccarelli, P. Sette, P. Pierro, et al.
Diverse patterns of non-adherence are associated with differently impaired genotypic resistence test at HAART virological failure.
Program and abstracts: 4th International Conference on HIV Treatment Adherence, pp. 176
Copyright © 2011. Sociedad Española de Farmacia Hospitalaria
Opciones de artículo
Herramientas